<SEC-DOCUMENT>0001213900-25-039892.txt : 20250506
<SEC-HEADER>0001213900-25-039892.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250506070011
ACCESSION NUMBER:		0001213900-25-039892
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250506
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Tiziana Life Sciences Ltd
		CENTRAL INDEX KEY:			0001723069
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38723
		FILM NUMBER:		25915168

	BUSINESS ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB
		BUSINESS PHONE:		0044(0) 207-495-2379

	MAIL ADDRESS:	
		STREET 1:		3RD FLOOR, 11-12 ST. JAMES'S SQUARE
		CITY:			LONDON, ENGLAND
		STATE:			X0
		ZIP:			SW1Y 4LB

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Tiziana Life Sciences plc
		DATE OF NAME CHANGE:	20171116
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0241041-6k_tiziana.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO RULE 13a-16 OR 15d-16</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>May 2025</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Commission File Number:</B>&nbsp; <B>001-38723</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tiziana Life Sciences LTD</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>9<SUP>th</SUP>&nbsp;Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>107
Cheapside</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>London
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: #202124"><FONT STYLE="background-color: white"><B>EC2V
6DN</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of registrant&rsquo;s principal executive
office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-left: auto; margin-right: auto; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant files or will file annual
reports under cover of Form&nbsp;20-F or Form&nbsp;40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">Form&nbsp;20-F&nbsp;</FONT>&#9746;<FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Form&nbsp;40-F&nbsp;</FONT>&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION CONTAINED IN THIS REPORT ON FORM&nbsp;6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On May 6, 2025, Tiziana Life Sciences LTD (the &ldquo;<U>Company</U>&rdquo;)
issued this 6K announcing, promising results from an open-label clinical study evaluating nasal foralumab, the world&rsquo;s only fully
human anti-CD3 monoclonal antibody administered intranasally, for the treatment of non-active secondary progressive multiple sclerosis
(na-SPMS). This comprehensive study demonstrated that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial
activation, and stabilized clinical progression in patients suffering from progression independent of relapse activity (PIRA)&mdash;a
major unmet need in the treatment of MS, and a key disease endpoint for intranasal foralumab development. The article is titled &ldquo;Nasal
foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active
secondary progressive MS.&rdquo; This study is the first to integrate, F18TSPO PET, Proteomics, and Clinical assessments in na-SPMS. These
findings in MFIS score reduction are a critically important Quality of Life (QoL) measure for patients with MS., a copy of which is furnished
as Exhibit 99.1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Announcement is furnished herewith as Exhibit
99.1 to this Report on Form&nbsp;6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor
shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities
Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TIZIANA LIFE SCIENCES LTD</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 31%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: May 6, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;Keeren Shah</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Chief Financial Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT&nbsp;INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ea024104101ex99-1_tiziana.htm">Tiziana Life Sciences LTD Press Release, dated May 6, 2025</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea024104101ex99-1_tiziana.htm
<DESCRIPTION>TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED MAY 6, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B><IMG SRC="ex99-1_001.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; color: Red"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 12pt"><B>Tiziana Life
Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Meaningful Fatigue score reduction seen in study is a critically important
quality of life (QoL) measure for Multiple Sclerosis patients. </B></FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>All patients experienced stabilization of Expanded Disability Status Scale
(EDSS) scores.</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>TSPO-PET imaging showed significant reductions in microglial activation
at six months (p&lt;0.05).</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">NEW YORK, May 6, 2025 &ndash; Tiziana Life Sciences, Ltd. (Nasdaq:
TLSA) (&ldquo;Tiziana&rdquo; or the &ldquo;Company&rdquo;), a biotechnology company developing breakthrough immunomodulation therapies
with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced promising results
from an open-label clinical study evaluating nasal foralumab, the world&rsquo;s only fully human anti-CD3 monoclonal antibody administered
intranasally, for the treatment of non-active secondary progressive multiple sclerosis (na-SPMS). This comprehensive study demonstrated
that nasal foralumab was safe, induced potent regulatory immune responses, reduced microglial activation, and stabilized clinical progression
in patients suffering from progression independent of relapse activity (PIRA)&mdash;a major unmet need in the treatment of MS, and a key
disease endpoint for intranasal foralumab development. The article is titled &ldquo;Nasal foralumab treatment of PIRA induces regulatory
immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS.&rdquo; This study
is the first to integrate, F18TSPO PET, Proteomics, and Clinical assessments in na-SPMS. These findings in MFIS score reduction are a
critically important Quality of Life (QoL) measure for patients with MS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Study Highlights:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Ten patients with na-SPMS, who continued to progress despite B-cell therapy,
were treated with nasal foralumab for a minimum of six months.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No serious or severe treatment-related adverse events were reported.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">All patients experienced stabilization of their Expanded Disability Status
Scale (EDSS) scores; three of four patients that were treated continuously for 12 months showed improvement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Fatigue, a major symptom burden in MS, improved in six out of ten patients,
as measured by the Modified Fatigue Impact Scale (MFIS).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Total MFIS scores correlated strongly with mGALP scores in the hippocampus
(r=0.89, p=0.007) at baseline.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">No new T2 lesions were observed on MRI.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">TSPO-PET imaging showed significant reductions in microglial activation at
six months (p&lt;0.05).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Single-cell RNA sequencing revealed early and sustained changes in peripheral
immune cells, including increased regulatory T cells (Tregs) and expression of TGF&beta; across multiple cell types.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;Our findings mark a significant advancement for patients living
with non-active Secondary Progressive MS, who currently have very limited treatment options,&rdquo; said Tanuja Chitnis, M.D., Principal
Investigator and Professor of Neurology at Harvard Medical School and senior neurologist at Brigham and Women&rsquo;s Hospital, a founding
member of Mass General Brigham Healthcare System. &ldquo;Nasal administration of foralumab represents a novel, non-invasive approach that
not only induces regulatory immunity but also reduces harmful CNS inflammation.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PIRA and progressive forms of MS are characterized by central nervous
system-centric inflammation driven by microglial activation, processes not adequately addressed by existing therapies. Traditional MS
treatments targeting B-cells and cell trafficking have limited efficacy in managing progression behind the blood-brain barrier.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Nasal foralumab leverages the mucosal immune system to induce regulatory
immune responses, offering a novel mechanism to suppress CNS inflammation without the systemic immunosuppression seen with intravenous
therapies. Previous studies showed that nasal anti-CD3 could treat progressive MS in animal models by expanding LAP+ and IL-10+ Tregs,
providing the scientific rationale for this human study.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In parallel with these encouraging results, Tiziana Life Sciences has
initiated a randomized, double-blind, placebo-controlled Phase 2 clinical trial to further assess the efficacy and safety of nasal foralumab
in a larger cohort of patients with na-SPMS. This trial is expected to reach top line data read out at the end of 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;We are incredibly excited by these results, which validate the
potential of nasal foralumab to fundamentally shift the treatment paradigm for progressive MS,&rdquo; said Ivor Elrifi, Chief Executive
Officer of Tiziana Life Sciences. &ldquo;We are also committed to advancing this promising therapy into other larger clinical studies,
such as Alzheimer&rsquo;s Disease and ALS as quickly as possible.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This article has been submitted for peer review, and the full preprint
is available here: https://www.medrxiv.org/content/10.1101/2025.04.30.25326602v1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Foralumab</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological
drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 10 patients with Non-Active Secondary
Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328)
with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently
being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active
secondary progressive multiple sclerosis (NCT06292923).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb)
currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November
of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative
human diseases.<SUP>[1],[2]</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Tiziana Life Sciences</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tiziana Life Sciences is a clinical-stage biopharmaceutical company
developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana&rsquo;s
innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous
(IV) delivery. Tiziana&rsquo;s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical
development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana&rsquo;s technology
for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline
applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For more information about Tiziana Life Sciences and its innovative
pipeline of therapies, please visit www.tizianalifesciences.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0px; margin-bottom: 0px; width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">[1]</TD><TD STYLE="text-align: justify">https://www.pnas.org/doi/10.1073/pnas.2220272120</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left">[2]</TD><TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pnas.org/doi/10.1073/pnas.2309221120</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based on the Company&rsquo;s current expectations, estimates, and projections
about its industry, its beliefs, and assumptions. Words such as &lsquo;anticipates,&rsquo; &lsquo;expects,&rsquo; &lsquo;intends,&rsquo; &lsquo;plans,&rsquo; &lsquo;believes,&rsquo; &rsquo;seeks,&rsquo; &lsquo;estimates,&rsquo;
and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance
and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company&rsquo;s control, are difficult
to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.
The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements,
which reflect the view of the Company only as of the date of this announcement. Actual results may differ materially from those indicated
by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions
and other factors described more fully in the section entitled &lsquo;Risk Factors&rsquo; in Tiziana&rsquo;s Annual Report on Form 20-F
for the year ended December 31, 2023, and other periodic reports filed with the Securities and Exchange Commission. The forward-looking
statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake
any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated
events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For further inquiries:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Tiziana Life Sciences Ltd</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Spencer, Business Development, and Investor Relations<BR>
+44 (0) 207 495 2379<BR>
email:&nbsp;info@tizianalifesciences.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  B )8# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^N#]MOX$_
MMJ_%S2KF?]F#]I^'X5V']FE'\&6NA6>FW^LSF//GV7Q%B2]U+3)9.?*B6UAM
MGWC?=0A ]?QT?M0_LN_M<:;XMU30?VC-?^*6N:W')+)//XUUW7?$*7D;R%?M
M=M?7E]?VU[93DCRKJTGFM2&$>Y''E#]+?VU/VAOVN_\ @EA^VKJ_A7X=?%#Q
M5?\ [/7Q4=?B3\//"/C&<^+/"^EV&K7[IXB\(Z9'K@N)]/M_#NM+/;6EMIM[
M:?9M)O-,X)9F?]+?V>?^"@/PU_;7\/VG@?X]?#GP[%KS+&+'6-&D5#'<7&(Q
M<6-GJ_F/:M(2!/:Q:E<V]PA,<D+ HI_;>&*68Y/EM+,/[+RK/\BGAX5YXC 4
ML+A,\PD&[3E4A6H\V,5&?-"O!UI37+>G42LC^%/%_,,AXGXIK<-4>-.*_#?C
M]YA/ X3!<15\VSGP^SRM"+J4*-"M@,=&.15,;04:N!Q$<+2H3E)T\10E)3DO
MY = ^ ?C_P &WBW7@[5M>\/Z@SJ89M$NM0TVY,@^Z4>REA<N.<$-G!//!K^B
MC_@F%^PC^VI\4+O2?BA\=_VGOVB?!GP.L+JWO=(\&Z5\4_&NEZI\1I;2972W
M"R:M)_9_@\O%Y5]>"(2:NFZUTW;;F2]K]>-4_95_9;^#,;?$/Q;H]MJ^F6!%
M['IIM;5[261993;6K/</#%':MY#R/;23LUPT4\3S/:QM&_Y!?M^_\%AO'::1
MK?P\^!36WPY\,0VTFD-K&BNO_"07MND;6_V6RU%(H8]&M3'MB1-'MXYTC!5+
M]1P/2Q>-GQ=AYX7A?*:>'IZK'YYFM'"JE@Z<GR>RP=.6'J5ZV,G[RYH0YJ:3
M5-QG>M2^5R7#8GP<S/#YAXO\;ULWQ=5I\,^'W!6)S:IC\\Q-.*K?7<]Q+S&E
M@,!D="+HRY*M>,<5*<'B55HNG@<5_2]X0^+?PW\6>-?&/PO\'^)K/7_$_P ,
M+714\:66GS-?)X<FU>.?^R]-U/4 7B_M>6"SFGGLS-)=P(%>Z"/)BOR^_P""
MLO\ P5W\(?\ !,!OV;+*X\$Z#\5-<^.OQFT/X<:[X?/Q"TOPKK/@+PKJGD^?
MXZO-/EM-1N[BQC:4QV[7,-C8/)$XEOHURRY'_!"CX9:[X;_8]N_BWXM6YD\3
M?'[Q[K7CC[7?;WO;KPWIPCT'0+B6>;=/,E\UGJ.II+*\C3+?"<NYDW'\*O\
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MEJUTUCI=WXU\4:+X9M]1O$3S)+6QEUF]LTNIXXR'>* NZ*59@ PS^$'[>/\
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M&B6<>G/I025+9;Z\#;D%%WY+T5M@Y5OKLUN^NCL?H!^R-\&-6_9T_9<_9\^
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M_AW4].BU_3UBN+B);/5DN[98YYD$865PW]L<))AB))),49)/))*#))[DT44
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7:EH^E6=Y'8:IJ-FDPM[ZYCE*** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
